WO2024079317A1 - Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies - Google Patents
Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies Download PDFInfo
- Publication number
- WO2024079317A1 WO2024079317A1 PCT/EP2023/078486 EP2023078486W WO2024079317A1 WO 2024079317 A1 WO2024079317 A1 WO 2024079317A1 EP 2023078486 W EP2023078486 W EP 2023078486W WO 2024079317 A1 WO2024079317 A1 WO 2024079317A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- aav
- alpha
- cyp46a1
- synucleinopathies
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 208000032859 Synucleinopathies Diseases 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 239000013598 vector Substances 0.000 claims abstract description 98
- 102000020038 Cholesterol 24-Hydroxylase Human genes 0.000 claims abstract description 59
- 108091022871 Cholesterol 24-Hydroxylase Proteins 0.000 claims abstract description 59
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 20
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 14
- 208000018737 Parkinson disease Diseases 0.000 claims description 21
- 239000013607 AAV vector Substances 0.000 claims description 18
- 241000702421 Dependoparvovirus Species 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 210000004556 brain Anatomy 0.000 abstract description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 230000004900 autophagic degradation Effects 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000013459 approach Methods 0.000 abstract description 3
- 230000007170 pathology Effects 0.000 abstract description 3
- 230000037361 pathway Effects 0.000 abstract description 3
- 230000002950 deficient Effects 0.000 abstract description 2
- 230000000626 neurodegenerative effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 57
- 241000699670 Mus sp. Species 0.000 description 43
- 239000007924 injection Substances 0.000 description 31
- 238000002347 injection Methods 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 30
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 29
- 102100026882 Alpha-synuclein Human genes 0.000 description 20
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 19
- 108090000185 alpha-Synuclein Proteins 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 210000002569 neuron Anatomy 0.000 description 17
- 210000003169 central nervous system Anatomy 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 210000001577 neostriatum Anatomy 0.000 description 12
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 210000003523 substantia nigra Anatomy 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 7
- 102000003425 Tyrosinase Human genes 0.000 description 7
- 108060008724 Tyrosinase Proteins 0.000 description 7
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 210000001259 mesencephalon Anatomy 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 210000005064 dopaminergic neuron Anatomy 0.000 description 6
- 230000003291 dopaminomimetic effect Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- ZPBYVFQJHWLTFB-UHFFFAOYSA-N 3-methyl-7H-purin-6-imine Chemical compound CN1C=NC(=N)C2=C1NC=N2 ZPBYVFQJHWLTFB-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102200036626 rs104893877 Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 4
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 229930192649 bafilomycin Natural products 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3MeA Natural products CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
- 101100385065 Homo sapiens CYP46A1 gene Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000013473 artificial intelligence Methods 0.000 description 3
- 239000012822 autophagy inhibitor Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000008150 cryoprotective solution Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940049268 euthasol Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- -1 olive oil Chemical compound 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010825 rotarod performance test Methods 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- IOWMKBFJCNLRTC-XWXSNNQWSA-N (24S)-24-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](O)C(C)C)[C@@]1(C)CC2 IOWMKBFJCNLRTC-XWXSNNQWSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241001573498 Compacta Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 108700005000 Glial Fibrillary Acidic Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000001246 colloidal dispersion Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 238000013427 histology analysis Methods 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 230000007441 retrograde transport Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000958487 Adeno-associated virus 3B Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000269627 Amphiuma means Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 description 1
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000007873 MPTP Poisoning Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000017299 Synapsin-1 Human genes 0.000 description 1
- 108050005241 Synapsin-1 Proteins 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004642 autophagic pathway Effects 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007356 neuronal autophagy Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 102220031971 rs431905511 Human genes 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000001587 telencephalon Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000008419 α-Syn pathology Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13098—Cholesterol 24-hydroxylase (1.14.13.98)
Abstract
The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerative pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD. Thus the present invention relates to a vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
Description
METHODS AND PHARMACEUTICAL COMPOSITION FOR THE
TREATMENT OF ALPHA- SYNUCLEINOPATHIES
FIELD OF THE INVENTION:
The present invention relates to a vector for use in the treatment of alpha- synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
BACKGROUND OF THE INVENTION:
Disturbances in brain cholesterol metabolism play an important role in neurodegenerative diseases including Alzheimer Disease (AD), Huntington Disease (HD), Spinocerebellar Ataxias (Sea) and Parkinson Disease (PD). In particular, the cholesterol 24- hydroxylase (CYP46A1), the key neuronal enzyme that converts excess of cholesterol into 24- hydroxy cholesterol and ensures the turnover of brain cholesterol is decreased in affected brain regions in patients with AD, HD, Sca3. These diseases have in common the accumulation of misfolded proteins that aggregate and are toxic for neuronal cells. Studies from NEUROGENCELL lab showed that restoring CYP46A1 and cerebral cholesterol metabolism is a potentially relevant therapeutic strategy for AD (Hudry E, et al. 2010 and Burlot et al. 2015), HD, SC A and ALS (Wurtz G; et al. 2022). A single injection of an adeno-associated vector (AAV) encoding for CYP46A1 in affected brain regions effectively reduces aggregated proteins, restores several key cellular functions such as transcription activity, vesicular transport, synaptic transmission, endocytosis and autophagy, and promotes neuronal survival. Interestingly, in PD, a decrease in plasmatic 24-hydroxycholesterol levels in patients, suggests a possible alteration in brain cholesterol metabolism. In addition, studies demonstrated that cholesterol and alpha-synuclein are closely linked in cellular compartments. Moreover, neuronal autophagy defects are believed to be crucially involved in PD pathogenesis.
SUMMARY OF THE INVENTION:
In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV-CYP46A1 delivery, as evidenced in several neurodegenerative
pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD.
Thus, the invention relates to a vector for use in the treatment of alpha- synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
Particularly, the invention is defined by its claims.
DETAILED DESCRIPTION OF THE INVENTION:
The CYP46A1 sequences and used thereof
A first object of the invention relates to a vector for use in the treatment of alpha- synucleinopathies in a subject in need thereof, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
In a particular embodiment, the invention relates to a vector for use in the treatment of Lewy body diseases in a subject in need thereof, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
As used herein, the term “alpha-synucleinopathies” denotes incorporates clinical diseases such as Parkinson disease (PD), PD with dementia, dementia with Lewy bodies, and multiple-system atrophy (MSA).
In some embodiment, the alpha-synucleinopathy is not Alzheimer Disease (AD).
As used herein, the term “gene” refers to a polynucleotide containing at least one open reading frame that is capable of encoding a particular polypeptide or protein after being transcribed or translated.
As used herein, the terms “coding sequence” or “a sequence which encodes a particular protein” or “encoding nucleic acid”, denotes a nucleic acid sequence which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences.
The CYP46A1 gene encodes cholesterol 24-hydroxylase. This enzyme is a member of the cytochrome P450 superfamily. A cDNA sequence for CYP46A1 is disclosed in Genbank
Access Number AF094480.1 (SEQ ID NO: 1). The amino acid sequence is shown in SEQ ID NO:2.
SEQ ID NO: 1 : atgagccccg ggctgctgct gctcggcagc gccgtcctgc tcgccttcgg cctctgctgc accttcgtgc accgcgctcg cagccgctac gagcacatcc ccgggccgcc gcggcccagt ttccttctag gacacctccc ctgcttttgg aaaaaggatg aggttggtgg ccgtgtgctc caagatgtgt ttttggattg ggctaagaag tatggacctg ttgtgcgggt caacgtcttc cacaaaacct cagtcatcgt cacgagtcct gagtcggtta agaagttcct gatgtcaacc aagtacaaca aggactccaa gatgtaccgt gcgctccaga ctgtgtttgg tgagagactc ttcggccaag gcttggtgtc cgaatgcaac tatgagcgct ggcacaagca gcggagagtc atagacctgg ccttcagccg gagctccttg gttagcttaa tggaaacatt caacgagaag gctgagcagc tggtggagat tctagaagcc aaggcagatg ggcagacccc agtgtccatg caggacatgc tgacctacac cgccatggac atcctggcca aggcagcttt tgggatggag accagtatgc tgctgggtgc ccagaagcct ctgtcccagg cagtgaaact tatgttggag ggaatcactg cgtcccgcaa cactctggca aagttcctgc cagggaagag gaagcagctc cgggaggtcc gggagagcat tcgcttcctg cgccaggtgg gcagggactg ggtccagcgc cgccgggaag ccctgaagag gggcgaggag gttcctgccg acatcctcac acagattctg aaagctgaag agggagccca ggacgacgag ggtctgctgg acaacttcgt caccttcttc attgctggtc acgagacctc tgccaaccac ttggcgttca cagtgatgga gctgtctcgc cagccagaga tcgtggcaag gctgcaggcc gaggtggatg aggtcattgg ttctaagagg tacctggatt tcgaggacct ggggagactg cagtacctgt cccaggtcct caaagagtcg ctgaggctgt acccaccagc atggggcacc tttcgcctgc tggaagagga gaccttgatt gatggggtca gagtccccgg caacaccccg ctcttgttca gcacctatgt catggggcgg atggacacat actttgagga cccgctgact ttcaaccccg atcgcttcgg ccctggagca cccaagccac ggttcaccta cttccccttc tccctgggcc accgctcctg catcgggcag cagtttgctc agatggaggt gaaggtggtc atggcaaagc tgctgcagag gctggagttc cggctggtgc ccgggcagcg cttcgggctg caggagcagg ccacactcaa gccactggac cccgtgctgt gcaccctgcg gccccgcggc tggcagcccg cacccccacc acccccctgc tgagggggcc tccaggcagg acgagactcc tcgggcaagg gccgtgcccg cccacctctg ctgcccacgg ccacccaccc ttctcccctg ccccgtcccc tgggccaccc ttcacgctgg cttccagcgg gccctctgcc gaccgcctgc ttcacacccc tcagcgctcc ctgtcgcctg cggactccat ggcccttcct ggactggccc ttgcccaact cccagccacc accactgtcc ctaccactga gcccttgcac aggccacttg ctcagacgag acaccctaac tcttgctcac tccctaaagc cctcttcagg ggtcacctcc tccaagaagc cctccttgcc accccccgcc ggcaggggcc cctcctctgt gctccctcgg tcacctgtgc tacctctaac accacactga ccacactgta tcgtgagtgt ccgttgacgt gaccaattgc cctgccaggc tgtcagcgcc tcaagggtag ggtctgcgtg tgatttgtct ctgagccccc tgtgcccacc cagggcccgg cacagagtcg atgctcaata aatgtgtgtt gactgcaaaa aaaaaaaaaa aaaaaaaaaa
SEQ ID NO: 2:
MSPGLLLLGS AVLLAFGLCC TFVHRARSRY EHIPGPPRPS FLLGHLPCFW KKDEVGGRVL QDVFLDWAKK YGPVVRVNVF HKTSVIVTSP ESVKKFLMST KYNKDSKMYR ALQTVFGERL FGQGLVSECN YERWHKQRRV IDLAFSRSSL VSLMETFNEK AEQLVEILEA KADGQTPVSM QDMLTYTAMD ILAKAAFGME
TSMLLGAQKP LSQAVKLMLE GITASRNTLA KFLPGKRKQL REVRESIRFL RQVGRDWVQR RREALKRGEE VPADILTQIL KAEEGAQDDE GLLDNFVTFF IAGHETSANH LAFTVMELSR QPEIVARLQA EVDEVIGSKR YLDFEDLGRL
QYLSQVLKES LRLYPPAWGT FRLLEEETLI DGVRVPGNTP LLFSTYVMGR
MDTYFEDPLT FNPDRFGPGA PKPRFTYFPF SLGHRSCIGQ QFAQMEVKVV
MAKLLQRLEF RLVPGQRFGL QEQATLKPLD PVLCTLRPRG WQPAPPPPPC
In a preferred embodiment, the invention provides a nucleic acid construct comprising sequence SEQ ID N°1 or a variant thereof for the treatment of alpha-synucleinopathies.
The variants include, for instance, naturally-occurring variants due to allelic variations between individuals (e.g., polymorphisms), alternative splicing forms, etc. The term variant also includes CYP46A1 gene sequences from other sources or organisms. Variants are preferably substantially homologous to SEQ ID No 1, i.e., exhibit a nucleotide sequence identity of typically at least about 75%, preferably at least about 85%, more preferably at least about 90%, more preferably at least about 95% with SEQ ID No 1. Variants of a CYP46A1 gene also include nucleic acid sequences, which hybridize to a sequence as defined above (or a complementary strand thereof) under stringent hybridization conditions. Typical stringent hybridisation conditions include temperatures above 30° C, preferably above 35°C, more preferably in excess of 42°C, and/or salinity of less than about 500 mM, preferably less than 200 mM. Hybridization conditions may be adjusted by the skilled person by modifying the temperature, salinity and/or the concentration of other reagents such as SDS, SSC, etc.
As used herein, the term "subject" denotes a mammal, such as a rodent, a feline, a canine, and a primate. Particularly, a subject according to the invention is a human. Particularly, a subject according to the invention is a human with an alpha-synucleinopathie.
As used herein, the term "treatment" or "treat" refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subjects at risk of contracting the disease or suspected to have contracted the disease as well as subjects who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. The treatment may be administered to a subject having
a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment. By "therapeutic regimen" is meant the pattern of treatment of an illness (e.g., the pattern of dosing used during therapy). A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease. The general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen. An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering a drug at regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
The invention also relates to a method of treating alpha-synucleinopathies in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a vector which comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
Non viral vectors
In a preferred embodiment, the vector use according to the invention is a non viral vector. Typically, the non viral vector may be a plasmid encoding CYP46A1.
Viral vectors
Gene delivery viral vectors useful in the practice of the present invention can be constructed utilizing methodologies well known in the art of molecular biology. Typically, viral vectors carrying transgenes are assembled from polynucleotides encoding the transgene,
suitable regulatory elements and elements necessary for production of viral proteins which mediate cell transduction.
The terms “Gene transfer” or “gene delivery” refer to methods or systems for reliably inserting foreign DNA into host cells. Such methods can result in transient expression of non integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e. g. , episomes), or integration of transferred genetic material into the genomic DNA of host cells.
Examples of viral vector include adenoviral, retroviral, lentiviral, herpesvirus and adeno-associated virus (AAV) vectors.
Such recombinant viruses may be produced by techniques known in the art, such as by transfecting packaging cells or by transient transfection with helper plasmids or viruses. Typical examples of virus packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc. Detailed protocols for producing such replication-defective recombinant viruses may be found for instance in WO95/14785, WO96/22378, US5,882,877, US6,013,516, US4,861,719, US5,278,056 and WO94/19478.
In a preferred embodiment, adeno-associated viral (AAV) vectors are employed.
In another preferred embodiment, the AAV vector is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO and all variants of AAV9, including AAVPHP.eB, AAV3B, AAV-2i8, Rh74, AAV capBlO or any other serotypes of AAV that can infect human, monkeys or other species.
In a more preferred embodiment, the AAV vector is an AAVrhlO.
By an "AAV vector" is meant a vector derived from an adeno-associated virus serotype, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV6, etc. AAV vectors can have one or more of the AAV wild-type genes deleted in whole or part, preferably the rep and/or cap genes, but retain functional flanking ITR sequences. Functional ITR sequences are necessary for the rescue, replication and packaging of the AAV virion. Thus, an AAV vector is defined herein to include at least those sequences required in cis for replication and packaging (e. g., functional ITRs) of the virus. The ITRs need not be the wild-type nucleotide sequences, and may be altered, e. g , by the insertion, deletion or substitution of nucleotides, so long as the sequences provide for functional rescue, replication and packaging. AAV expression vectors are constructed using known techniques to at least provide as operatively linked components in the direction of transcription, control elements including a
transcriptional initiation region, the DNA of interest (i.e. the CYP46AI gene) and a transcriptional termination region.
The control elements are selected to be functional in a mammalian cell. The resulting construct which contains the operatively linked components is bounded (5'and Y) with functional AAV ITR sequences. By "adeno-associated virus inverted terminal repeats " or "AAVITRs" is meant the art-recognized regions found at each end of the AAV genome which function together in cis as origins of DNA replication and as packaging signals for the virus. AAV ITRs, together with the AAV rep coding region, provide for the efficient excision and rescue from, and integration of a nucleotide sequence interposed between two flanking ITRs into a mammalian cell genome. The nucleotide sequences of AAV ITR regions are known. See, e. g., Kotin, 1994; Berns, KI "Parvoviridae and their Replication" in Fundamental Virology, 2nd Edition, (B. N. Fields and D. M. Knipe, eds. ) for the AAV-2 sequence. As used herein, an "AAV ITR" does not necessarily comprise the wild-type nucleotide sequence, but may be altered, e. g., by the insertion, deletion or substitution of nucleotides. Additionally, the AAV ITR may be derived from any of several AAV serotypes, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV6, etc. Furthermore, 5'and 3'ITRs which flank a selected nucleotide sequence in an AAV vector need not necessarily be identical or derived from the same AAV serotype or isolate, so long as they function as intended, i. e., to allow for excision and rescue of the sequence of interest from a host cell genome or vector, and to allow integration of the heterologous sequence into the recipient cell genome when AAV Rep gene products are present in the cell. Additionally, AAV ITRs may be derived from any of several AAV serotypes, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV 5, AAV6, etc. Furthermore, 5'and 3'ITRs which flank a selected nucleotide sequence in an AAV expression vector need not necessarily be identical or derived from the same AAV serotype or isolate, so long as they function as intended, i. e., to allow for excision and rescue of the sequence of interest from a host cell genome or vector, and to allow integration of the DNA molecule into the recipient cell genome when AAV Rep gene products are present in the cell.
Particularly preferred are vectors derived from AAV serotypes having tropism for and high transduction efficiencies in cells of the mammalian CNS, particularly neurons. A review and comparison of transduction efficiencies of different serotypes is provided in Cearley CN et al., 2009. In one preferred example, AAV2 based vectors have been shown to direct long-term expression of transgenes in CNS, preferably transducing neurons. In other nonlimiting examples, preferred vectors include vectors derived from AAVrhIO serotype, which have also
been shown to transduce cells of the CNS and particularly the striatum or the substantia nigra (SN) and more particularly the substantia nigra pars compacta (SNpc).
The selected nucleotide sequence is operably linked to control elements that direct the transcription or expression thereof in the subject in vivo. Such control elements can comprise control sequences normally associated with the selected gene.
Alternatively, heterologous control sequences can be employed. Useful heterologous control sequences generally include those derived from sequences encoding mammalian or viral genes. Examples include, but are not limited to, the phophoglycerate kinase (PKG) promoter, CAG, neuronal promoters, promoter of Dopamine- 1 receptor and Dopamine-2 receptor, the SV40 early promoter, mouse mammary tumor virus LTR promoter; adenovirus major late promoter (Ad MLP); a herpes simplex virus (HSV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE), rous sarcoma virus (RSV) promoter, synthetic promoters, hybrid promoters, and the like. In addition, sequences derived from nonviral genes, such as the murine metallothionein gene, will also find use herein. Such promoter sequences are commercially available from, e. g. , Stratagene (San Diego, CA). For purposes of the present invention, both heterologous promoters and other control elements, such as CNS-specific and inducible promoters, enhancers and the like, will be of particular use.
Examples of heterologous promoters include the CMV promoter. Examples of CNS specific promoters include those isolated from the genes from myelin basic protein (MBP), glial fibrillary acid protein (GFAP), and neuron specific enolase (NSE).
Examples of inducible promoters include DNA responsive elements for ecdysone, tetracycline, hypoxia andaufin.
The AAV expression vector which harbors the DNA molecule of interest bounded by AAV ITRs, can be constructed by directly inserting the selected sequence (s) into an AAV genome which has had the major AAV open reading frames("ORFs") excised therefrom. Other portions of the AAV genome can also be deleted, so long as a sufficient portion of the ITRs remain to allow for replication and packaging functions. Such constructs can be designed using techniques well known in the art. See, e. g. , U. S. Patents Nos. 5,173, 414 and 5,139, 941; International Publications Nos. WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al., 1988 ; Vincent et al., 1990; Carter, 1992 ; Muzyczka, 1992 ; Kotin, 1994; Shelling and Smith, 1994 ; and Zhou et al., 1994. Alternatively, AAV ITRs can be excised from the viral genome or from an AAV vector containing the same and fused 5'and 3'of a selected nucleic acid construct that is present in another vector using
standard ligation techniques. AAV vectors which contain ITRs have been described in, e. g. , U. S. Patent no. 5,139, 941. In particular, several AAV vectors are described therein which are available from the American Type Culture Collection ("ATCC") under Accession Numbers 53222,53223, 53224,53225 and 53226. Additionally, chimeric genes can be produced synthetically to include AAV ITR sequences arranged 5'and 3'of one or more selected nucleic acid sequences. Preferred codons for expression of the chimeric gene sequence in mammalian CNS cells can be used. The complete chimeric sequence is assembled from overlapping oligonucleotides prepared by standard methods. See, e. g., Edge, 1981 ; Nambair et al., 1984 ; Jay et al., 1984. In order to produce rAAV virions, an AAV expression vector is introduced into a suitable host cell using known techniques, such as by transfection. A number of transfection techniques are generally known in the art. See, e. g. , Graham et al., 1973;, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis etal. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al., 1981. Particularly suitable transfection methods include calcium phosphate co-precipitation (Graham et al., 1973), direct microinjection into cultured cells (Capecchi, 1980), electroporation (Shigekawa et al., 1988), liposome mediated gene transfer (Mannino et al., 1988), lipid- mediated transduction (Feigner et al., 1987), and nucleic acid delivery using high-velocity microprojectiles (Klein et al., 1987).
For instance, a preferred viral vector, such as the AAVrhlO, comprises, in addition to a cholesterol 24-hydroxylase encoding nucleic acid sequence, the backbone of AAV vector with ITR derived from AAV-2, the promoter, such as the mouse PGK (phosphoglycerate kinase) gene or the cytomegalovirus/p-actin hybrid promoter (CAG) consisting of the enhancer from the cytomegalovirus immediate gene, the promoter, splice donor and intron from the chicken P-actin gene, the splice acceptor from rabbit P-globin, or any neuronal promoter such as the promoter of Dopamine- 1 receptor or Dopamine-2 receptor with or without the wild-type or mutant form of woodchuck hepatitis virus post-transcriptional regulatory element (WPRE).
Delivery of the vectors
It is herein provided a method for treating alpha-synucleinopathies in a subject, said method comprising:
(a) providing a vector as defined above, which comprises a cholesterol 24-hydroxylase encoding nucleic acid; and
(b) delivering the vector to the central nervous system (CNS), either directly to the substantia nigra or indirectly throught retrograde transport from the putamen of the subject, whereby said vector transduces cells in the CNS, and whereby cholesterol 24-hydroxylase is expressed by the transduced cells at a therapeutically effective level.
In a particular embodiment, the delivery of the vector in realized in the striatum or in the SNpc.
Methods of delivery of vectors to neurons and/or astrocytes includes generally any method suitable for delivery vectors to the neurons and/or astrocytes such that at least a portion of cells of a selected synaptically connected cell population is transduced. The vector may be delivered to any cells of the central nervous system, or both. Generally, the vector is delivered to the cells of the central nervous system, including for example cells of the spinal cord, brainstem (medulla, pons, and midbrain), cerebellum, diencephalon (thalamus, hypothalamus), telencephalon (corpus striatum, substantia nigra, cerebral cortex, or, within the cortex, the occipital, temporal, parietal or frontal lobes), or combinations thereof, or preferably any suitable subpopulation thereof. Further preferred sites for delivery include the ruber nucleus, corpus amygdaloideum, entorhinal cortex and neurons in ventralis lateralis, or to the anterior nuclei of the thalamus.
To deliver the vector specifically to a particular region and to a particular population of cells of the CNS, the vector may be administered by intracerebral injection. For example, patients have the stereotactic frame base fixed in place (screwed into the skull). The brain with stereotactic frame base (MRI compatible with fiducial markings) is imaged using high resolution MRI. The MRI images are then transferred to a computer which runs stereotactic software. A series of coronal, sagittal and axial images are used to determine the target (site of AAV vector injection) and trajectory. The software directly translates the trajectory into 3 dimensional coordinates appropriate for the stereotactic frame. Alternatively, neuronavigation can be used instead of the stereotactic procedure, depending on neurosurgeon preference. Bunholes are drilled above the entry site and the stereotactic apparatus positioned with the needle implanted at the given depth. The AAV vector is then injected at the target sites. Since the AAV vector integrates into the target cells, rather than producing viral particles, the subsequent spread of the vector is minor, and mainly a function of passive diffusion from the site of injection and of course the desired transsynaptic transport, prior to integration. The degree of diffusion may be controlled by adjusting the ratio of vector to fluid carrier.
Additional routes of administration may also comprise local application of the vector under direct visualization, e. g., superficial cortical application, or other nonstereotactic application. The vector may be delivered intraparenchymally, intraci stemally, intrathecally or intravenously and een intravenously couple with focused ultrasound to improve blood brain barrier crossing.
The target cells of the vectors of the present invention are cells of the central nervous systems of a subject afflicted with alpha-synucleinopathies and more particularly the cells of the SNpc. However, neurons from the striatum are also targeted cells as they project into the SNpc and allow indirect tard-getting of the cells with less invasive surgery. Preferably the subject is a human being, generally an adult.
However the invention encompasses delivering the vector to biological models of the disease. In that case, the biological model may be any mammal at any stage of development at the time of delivery, e. g., embryonic, fetal, infantile, juvenile or adult, preferably it is an adult. Furthermore, the target CNS cells may be essentially from any source, especially nonhuman primates and mammals of the orders Rodenta (mice, rats, rabbit, hamsters), Carnivora (cats, dogs), and Arteriodactyla (cows, pigs, sheep, goats, horses) as well as any other non-human system (e. g. zebrafish model system).
Preferably, the method of the invention comprises intracerebral administration through stereotaxic injections. However, other known delivery methods may also be adapted in accordance with the invention. For example, for a more widespread distribution of the vector across the CNS, it may be injected into the cerebrospinal fluid, e. g. , by lumbar puncture. To direct the vector to the peripheral nervous system, it may be injected into the spinal cord or into the peripheral ganglia, or the flesh (subcutaneously or intramuscularly) of the body part of interest. In certain situations the vector can be administered via an intravascular approach. For example, the vector can be administered intra-arterially (carotid) in situations where the bloodbrain barrier is disturbed or not disturbed. Moreover, for more global delivery, the vector can be administered during the "opening" of the blood-brain barrier achieved by infusion of hypertonic solutions including mannitol.
The vectors used herein may be formulated in any suitable vehicle for delivery. For instance they may be placed into a pharmaceutically acceptable suspension, solution or emulsion. Suitable mediums include saline and liposomal preparations. More specifically, pharmaceutically acceptable carriers may include sterile aqueous of non-aqueous solutions,
suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.
A colloidal dispersion system may also be used for targeted gene delivery. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
The preferred doses and regimen may be determined by a physician, and depend on the age, sex, weight, of the subject, and the stage of the disease. As an example, for delivery of cholesterol 24-hydroxylase using a viral expression vector, each unit dosage of cholesterol 24- hydroxylase expressing vector may comprise 2.5 to 500 pl of a composition including a viral expression vector in a pharmaceutically acceptable fluid at a concentration ranging from 1011 tolO16 viral genome per ml for example.
Pharmaceutical composition
A second object of the invention concerns a pharmaceutical composition for use in the treatment of alpha-synucleinopathies in a subject in need thereof which comprises a therapeutically effective amount of a vector according to the invention.
Particularly, the invention concerns a pharmaceutical composition for use in the treatment of Lewy body diseases in a subject in need thereof, which comprises a therapeutically effective amount of a vector according to the invention.
By a "therapeutically effective amount" is meant a sufficient amount of the vector of the invention to treat alpha-synucleinopathies at a reasonable benefit/risk ratio applicable to any medical treatment.
It will be understood that the total daily dosage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed,
the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the products may be varied over a wide range per adult per day. The therapeutically effective amount of the vector according to the invention that should be administered, as well as the dosage for the treatment of a pathological condition with the number of viral or non-viral particles and/or pharmaceutical compositions of the invention, will depend on numerous factors, including the age and condition of the patient, the severity of the disturbance or disorder, the method and frequency of administration and the particular peptide to be used.
The presentation of the pharmaceutical compositions that contain the vector according to the invention may be in any form that is suitable for intraparenchymal, intracisternal, intracerebral, intrathecal, intraventricular or intravenous administration.
In the pharmaceutical compositions of the present invention for intramuscular, intravenous, intracerebral, intrathecal, intraventicular, intraparenchymal or intracisternal administration, the active principle, alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings.
Preferably, the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The vector according to the invention can be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
Multiple doses can also be administered.
The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
FIGURES:
Figure 1: CYP46A1 overexpression decreases the levels of alpha-synuclein protein in the human SH-SY5Y cell line by promoting the activation of autophagy.
A. Representative western blot from SH-SY5Ycells co-transfected with a plasmid expressing WT alpha-synuclein and a plasmid encoding either CYP46A1 or GFP. Cotransfected cells were treated with specific autophagy inhibitors 3 -methyladenine (3MA) and bafilomycin Al (Baf).
B. Densitometric analysis showed that CYP46A1 expression leads to a significant decrease in alpha-synuclein levels even in presence of autophagy inhibitors.
C. Densitometric analysis showed a significant increase in LC3B-II levels compared to LC3B-I levels suggesting an autophagy activation upon CYP46A1 expression.
Figure 2: Design of the POC in the model with alpha-synuclein fibrils injection.
Figure 3: Endogenous CYP46A1 protein level in MPTP mouse model.
Figure 4: Unbiased stereological estimation of TH-positive neurons count in the mouse SNpc 30 days after the last MPTP injection.
Figure 5: TH+ neurons count by level in the mouse SNpc 30 days after the last MPTP injection.
Figure 6: Protection of dopaminergic neurons loss with CYP46A1 in the C3 SNpc level 30 days after the last MPTP injection.
Figure 7: Alpha-synuclein pathology is significantly reduced when mice are treated with an AAV-CYP46A1 vector.
A. Bright-field microscopy images showing mouse midbrains with phosphorylated alpha-synuclein immunolabelled
B. Quantification of phospho-alpha-synuclein positive cells in the midbrain of alpha- synuclein A53T mice treated or not with an AAV-CYP46A1
Figure 8: Nigrostriatal degeneration is significantly reduced by AAV-CYP46A1 in the Neuromelanin PD mouse model
A. Unbiased stereological estimation of TH-positive neurons in the mouse SNpc 2 months after AAVs injection
B. Quantification of dopaminergic terminals in the mouse striatum by optical density measurement
Figure 9: The motor function of Neuromelanin mice treated with AAV-CYP46A1 is significantly less impaired because of the preservation of nigrostriatal degeneration.
A. Mean latency to fall at the Rotarod test during the months following AAVs injection
B. Graph showing forelimb stride length assessed at the Catwalk test at 2 months postinjection of AAVs
C. Graph showing hind limbs stride length assessed at the Catwalk test at 2 months post-injection of AAVs
EXAMPLES:
Example 1: in vitro model of human alpha-synuclein overexpression
Material and Methods:
Alpha-synuclein untagged constructs
Alpha-synuclein (WT or A53T) human cDNA were amplified by PCR from previously described vectors kindly provided by Addgene (plasmids #102361 and 105727). The PCR products were cloned in the Hindlll/Xba I sites of the pcDNA3.1 vector.
Cell Culture and transfection
Human neuroblastoma (SH-SY5Y) cells were grown in DMEM with Glutamax (Gibco) with 10% fetal bovine serum (Gibco), 100 U/ml penicillin, and 100 ug/ml streptomycin (Gibco) in 5% CO2 at 37°C. Cells were transiently transfected with plasmids using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions. pcDNA3-EGFP and pAAV-HA-CYP46Al plasmids were provided by Addgene (plasmid #13031). Experiments were initiated 24 h after transfection. For autophagy inhibition, cells were incubated for 24H by addition of 3 methyladenine or bafilomycin Al. 3
methyladenine (Millipore) or Bafilomycin Al (Sigma) were dissolved respectively in cell medium to a final concentration of 5 mM or 50 nM
Protein extraction and western-blot analysis
Cell pellets were homogenized in TENGEN buffer (150 mM NaCl, 50 mM Tris pH7.4, 1% Triton X-100) containing fresh protease inhibitor for 30 min at 4°C. Whole lysates were clarified by centrifugation at 10,000 rpm for 15 min. Proteins were quantified using Pierce BCA Protein Assay Kit (Thermo Scientific) by comparison with bovine serum albumin (BSA) standards. Equal volumes of each sample were separated by SDS-PAGE. Protein samples were denatured for 3 min at 95°C and separated on 4-20% SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Bio-Rad)). Membranes were blocked with 5% BSA in Trisbuffered saline (TBS) pH 8 for 1 h, followed by incubation with primary antibodies (see below) for 16 h at 4°C (1 :1000). Membranes were washed for 10 min three times in TBS with 0.1% Tween-20, incubated with LI-COR fluorescent secondary antibodies (Dylight 680 and Dylight 800) for 1 h at room temperature (1 :7500), and washed three more times with TBS with 0.1% Tween-20. A Li-COR Odyssey fluorescence scanner was used to capture images of the membranes.
Antibodies
The following primary antibodies were used: rabbit anti-actin (Sigma, A2066); rabbit anti-GFP (Sigma, SAB301138); rabbit anti-HA (Cell Signaling, 3724) or mouse anti-alpha- synuclein antibody (Invitrogen, AHB0261). Secondary antibodies for immunoblotting were the appropriate goat anti-mouse or anti-rabbit IRDye 680RD or 800CW IgG (Odyssey LI-COR)
Results:
The inventors investigated in vitro the impact of CYP46A1 overexpression on wild-type (WT) a-syn. To this end, neuroblastoma (SH-SY5Y) cells were co-transfected with a plasmid expressing WT a-syn and a plasmid encoding either CYP46A1 or GFP. Western blot analysis showed a statistically significant reduction in WT a-syn protein levels with CYP46A1 compared to the GFP (Figures 1A, IB). CYP46A1 overexpression is also able to decrease the level of mutated A53T a-syn proteins in SH-SY5Y cells after co-transfection with a A53T a- syn plasmid (data not shown). To further investigate the mechanisms of CYP46A1 -mediated effects on a-syn clearance, co-transfected SH-SY5Y cells were treated with specific autophagy inhibitors 3 -methyladenine (3MA) and bafilomycin Al (Baf). Treatment of cells with 3-MA or Baf resulted in a clear increase of WT a-syn in cells even in the presence of CYP46A1 (Figures
1A, IB). Overexpression of CYP46A1 significantly increased levels of LC3B-II compared to LC3B-I, suggesting that CYP46A1 promotes autophagic degradation of a-syn (Figures 1A, 1C)
This suggests that CYP46A1, that was previously shown to restore impaired autophagy pathway by improving the maturation of autophagosomes, could have a beneficial effect in PD mice models, particularly in the synucleinopathy models.
Next, the inventors validated this hypothesis in vivo in PD mouse models of PD.
Example 2: alpha-synuclein fibrils model
Material and Methods:
In collaboration with Satoru Tada (Japan), the inventors generated a proof of concept in mice that received injection of mutated alpha-synuclein fibrils. Eight weeks old wild type mice received an unilateral injection of AAV9 encoding either a WT hCYP46Al or a mutated hCYP46Al which is not functionally active as a control in the substantia nigra par compacta (SNc). At eight weeks, animals received unilateral injection of G51D mutated human alphasynculein fibrils in the SNc. Mice were sacrificed at 12 weeks for analysis (Figure 2).
Results:
In mice that received the hCYP46Al WT, a significant prevention of TH positive cells was demonstrated, with a total number of TH positive cells quite similar to normal levels (data not shown).
Example 3: subchronic MPTP poisoning model
Material and Methods:
Subchronic MPTP intoxication
MPTP administration is performed at least 16 days after the stereotaxic delivery of AAV-CYP46A1 vector so that animals have the necessary recovery time and the vector is well expressed. Animals poisoned with this neurotoxin are transferred, the day before the poisoning protocol, to the chemical area of the animal facility and placed on a ventilated rack. The animals are weighed and identified with an indelible marker. They are placed in disposable plastic cages (MPTP constraints) with filter cover. A piece of cotton wool intended for nesting is placed in the cage in order to improve the environment of the animals. On the day of the intoxication, the MPTP is diluted in physiological serum (NaCl 0.9%) at a concentration of 2.5 mg / ml. The
volume injected does not exceed 280 pl / injection / mouse. The intraperitoneal injections of MPTP or physiological serum are carried out using 1 ml insulin syringes fitted with a 12.7 X 0.33 needle. Five injections of MPTP (30 mg / kg) at the rate of one injection per day are given over 5 consecutive days. The injections are alternated on the left and right side of the animal. The cages are placed in another ventilated cabinet, the temperature of which is set at 28 °C. In fact, it was found that mice poisoned with MPTP according to the diet indicated in this procedure suffered from hypothermia and heart failure for a limited period of time (less than 12 hours). These peripheral side effects can lead to the death of 1 to 10% of the workforce within 12 hours after poisoning, depending on the experience. The 10% rate is not fixed and corresponds to a high limit range. Furthermore, this experimental procedure does not cause severe behavior (such as convulsions), significant brain damage, or ischemia under narcosis. The hypothermia observed in the intoxicated animals justifies that they be placed at a higher temperature (28 °C) and under observation throughout the procedure and 72 hours beyond the poisoning, without changing the litter. Once the 72 hours have elapsed, the animals will be transferred to clean cages and returned to a chemical housing area, but at standard animal room temperature and under observation.
AA V plasmid design and vector production
AAV vectors were produced and purified by Atlantic Gene therapies (INSERM U1089, Nantes, France). Vector production has been described elsewhere (Hudry et al., 2010). The viral constructs for AAVrh. lO-GFP and AAVrh.lO-CYP46Al contained the expression cassette consisting of the human /NAz/genes, driven by a CMV early enhancer/chicken P-actin (CAG) synthetic promoter (CAG) surrounded by inverted terminal repeats (ITR) sequences of AAV2.
Tissue collection
Mice were anesthetized with pentobarbital (Euthasol 180 mg/kg) solution and perfused transcardially with phosphate buffered saline (PBS). Brains were collected and post-fixed in PFA 4% prior to inclusion for histology or immediately frozen in liquid nitrogen for biomolecular analysis. Different CNS tissues (ventral midbrain, striatum, frontal cortex and cerebellum) were dissected and crushed using a FastPrep-24™ homogenizer (MP Biomedicals) to extract proteins or RNA for western-blotting and RT-qPCR analys
Histological analysis
Coronal brain sections (20 pm) were cut on a freezing microtome (Leica), collected serially in a cryoprotective solution, and stored at -20°C until use. Immunostainings were
carried out on frozen free-floating sections. Slices were washed in PBS O,1M and blocked in PBS O,1M Triton 0,03% containing 5% normal goat serum (NGS, Gibco) for 1 hour. Sections were then incubated with the respective primary antibody (see Antibodies section) in PBS- Triton 0,03% containing 3% NGS over night at 4°C. After three successive washes of 5 minutes in PBS, brain slices wete incubated for 1 hour and 30 minutes with seconday Alexa Fluorconjugated (Invitrogen) antibodies directed against the species of the primary antibody at room temperature. Slices were stained in a DAPI solution, mounted in Fluoromount-G™(Invitrogen) and conserved at 4°C until microscopy analysis. The immunoassayed slides were then scanned using a slide scanner (Axio Scan Z.l, Zeiss). Unbiased stereological counting in the SNpc was performed on 8 brain sections per mouse (from Cl to C8) to obtain the entire structure, then the number of cells was approximated by integral calculation. Positive cells were counted using artificial intelligence (Aiforia).
Antibodies
The following primary antibodies were used: rabbit anti-TH (Novus Biologicals, NB300-109) at 1 :2500; mouse anti-HA (Biolegend, 901516) at 1 : 1000. Secondary antibodies for immunoblotting were the appropriate goat anti-mouse or anti-rabbit Alexa-Fluor 488 or Alexa-Fluor 647 (Invitrogen)
Results:
First, the inventors demonstrated that administration of the AAV-CYP46A1 vector in the striatum allows, by retrograde transport, the expression of the transgenic CYP46A1 protein in the dopaminergic neurons (Tyrosine Hydroxylase (TH)-positive) of the SN (data not shown). Stereotaxic injection in mice is well tolerated. The expression of CYP46A1 in the striatum and the SNpc is rapid (plateau at D21 after injection) and stable (analyzed up to 12 months in mice and 6 months in primates). The enzyme is functional (increased 24OHC) and does not cause toxicity (data not shown).
Then, the inventors demonstrate a significant reduction of CYP46A1 expression in the SNpc of a PD mouse model, the MPTP model. MPTP is the only known dopaminergic neurotoxin capable of causing a clinical picture in humans and monkeys indistinguishable from PD. Its use is not technically difficult: it does not require any special equipment such as a stereotaxic frame, nor any surgical intervention on living animals such as 6-hydroxydopamine or rotenone. It is a reliable product and damage to the nigrostriatal dopaminergic pathway is reproducible, which is often not the case with other known toxins (Jackson-Lewis 2007).
CYP46A1 expression is reduced in the SNpc of MPTP mice 3 days after the last MPTP injection and there was no reduction of CYP46A1 expression in the striatum or a control region (frontal cortex) 3 days after the last injection (Figure 3).
The inventors also observed a protection of the TH-positive neurons loss induced by the CYP46A1 overexpression by immunofluorescence 30 days after the last MPTP injection in the whole SNpc (Figure 4). Indeed, MPTP intoxicated mice have an average of 3500 TH+ neurons per SNpc versus an average of 5500 TH-positive neurons with AAV-CYP46A1 treatment (of note, a C57BL/6J mouse has an average of 6000-7000 TH+ neurons per SNpc). This protection seems to be more significant in the SNpc than in other dopaminergic regions of the midbrain (data not shown).
In addition, among the regions of the SNpc significantly affected by MPTP intoxication (C3 and C6, Figure 5), a significant protection by the overexpression of CYP46A1 is observed by the counting of TH-positive neurons in 1/2 of the SNpc damaged by the MPTP and a trend of protection in the other 1/2 (Figure 6).
Example 4: alpha-synuclein vector-based model
Material and Methods:
Stereotaxic injections of AA Vs in the mouse brain
C57BL6/J 8-week-old mice were first analgesized by a subcutaneous injection of buprenorphine, then placed in an induction cage saturated with 4%-20% isoflurane-02 for 2 to 4 minutes and anesthesia maintained by inhalation of isoflurane in a face mask (1-1 ,5%-20%). Mice were positioned on a stereotaxic frame (Kopf) equipped with a 10 pL 1701 Hamilton syringe (Dutscher, 074493) and a tailor-made 32-gauge needle (Dutscher, 074753). A mixture of AAV9-SNCA-A53T and AAVrh. lO-CYP46Al or AAVrh. lO-C AG-null recombinant vectors was injected bilaterally into the mouse SNpc in a final volume of 1 pL at a rate of 0.2 pL/minute. Viral preparation corresponding to 1.109 vector genomes (vg)/SNpc for the AAVrh.10-CYP46A1 or the AAVrh.10-null and 1,5.1010 vg/SNpc for the AAV9-SNCA-A53T were injected into the right and the left SNpc at the stereotaxic coordinates: 2,9 mm caudal to the bregma, 1,3 mm lateral to midline and 4,2 mm ventral to the skull surface. The pipette was left in place for 5 min after injection to avoid leakage. After surgery, mice were placed in an incubator for optimized recovery from anaesthesia.
AA V plasmid design and vector production
Vector production has been described elsewhere (Hudry et al., 2010). The viral constructs for AAVrh.10- null and AAVrh.10-CYP46A1-HA contained the expression cassette consisting of the human /NAz/genes, driven by a CMV early enhancer/chicken P-actin (CAG) synthetic promoter (CAG) surrounded by inverted terminal repeats (ITR) sequences of AAV2. These vectors were produced and purified by Atlantic Gene therapies (INSERMU1089, Nantes, France).
AAV9-SNCA-A53T contained the expression cassette consisting of the human alpha- synuclein gene (SNCA) with the A53T mutation, driven by the human synapsin 1 (SYN1) synthetic promoter surrounded by inverted terminal repeats (ITR) sequences of AAV2, was produced and purchased on Vector Builder (P201129-1003).
Tissue collection
Mice were anesthetized with pentobarbital (Euthasol 180 mg/kg) solution and perfused transcardially with phosphate buffered saline (PBS). Brains were collected and post-fixed in PFA 4% prior to inclusion for histology analysis.
Histological analysis
Coronal brain sections (20 pm) were cut on a freezing microtome (Leica), collected serially in a cryoprotective solution, and stored at -20°C until use. Immunostainings were carried out on frozen free-floating sections. Slices were washed in PBS 0,lM and blocked in PBS 0,lM Triton 0,03% containing 5% normal goat serum (NGS, Gibco) for 1 hour. Sections were then incubated with the respective primary antibody (see Antibodies section) in PBS- Triton 0,03% containing 3% NGS over night at 4°C. After three successive washes of 5 minutes in PBS, brain slices wete incubated for 1 hour and 30 minutes with secondary Alexa Fluorconjugated (Invitrogen) antibodies directed against the species of the primary antibody at room temperature. Slices were stained in a DAPI solution, mounted in Fluoromount-G™(Invitrogen) and conserved at 4°C until microscopy analysis. The immunoassayed slides were then scanned using aNanoZoomer S60 digital slide scanner (Hamamatsu, C 13210-01) at 20X magnification. Unbiased stereological counting in the SNpc was performed on 8 brain sections per mouse (from Cl to C8) to obtain the entire structure, then the number of cells was approximated by integral calculation. Positive cells were counted using artificial intelligence (Aiforia).
Antibodies
The following primary antibody was used: rabbit anti-S129-alpha-synuclein (Abeam, ab51253). Secondary antibody for immunochemistry was the appropriate biotinylated goat antirabbit (Invitrogen).
Results:
The inventors investigated in vivo the impact of CYP46A1 in a mouse model of synucleopathy. To this end, an AAV vector (AAV9-SNCA-A53T) encoding for a mutated form of alpha-synuclein that is more prone to aggregation was injected into the SNpc of mice. This vector was co-administered with a vector encoding CYP46Al(AAV.rhlO-CYP46Al) or a control vector not encoding any protein (“empty vector”, EV: AAV.rhlO-null). The inventors wanted to demonstrate whether CYP46A1 could influence the onset and spread of alpha-syn pathology (aggregation of alpha-synuclein). To this end, the form of alpha-synuclein phosphorylated on serine 129 was detected by immunohistochemistry on mouse brain sections from the midbrain, including the SNpc. This phosphorylated form of alpha-synuclein (phospho- aSyn) is the in vivo marker of its aggregation. This immunorevelation was done in non-injected control mice (NI), alpha-synuclein non-treated mice (aSyn + EV) given AAV9-SNCA-A53T and AAVrh. lO-null vectors, and alpha-synuclein treated mice (aSyn + CYP46A1) given AAV9-SNCA-A53T and AAVrh. lO-CYP46Al vectors. The inventors show a visible decrease in phospho-aSyn in mice treated with CYP46A1 (Figure 7A, right panel).
The number of cells with positive phospho-aSyn inclusions was next assessed in the midbrain of alpha-synuclein mice treated or not with AAV-CYP46A1 and the inventors show a significant decrease in the number of phospho-aSyn positive cells in mice treated with CYP46A1 (Figure 7B). This confirms the positive role of CYP46A1 in autophagy and in the proteostatic mechanisms that help to manage alpha-synuclein aggregates in neurons.
This suggests that CYP46A1 could have a beneficial effect in PD mice models, particularly in the synucleinopathy models.
Example 5: neuromelanin vector-based model
Stereotaxic injections of AA Vs in the mouse brain
C57BL6/J 8-week-old mice were first analgesized by a subcutaneous injection of buprenorphine, then placed in an induction cage saturated with 4%-20% isoflurane-O2 for 2 to 4 minutes and anesthesia maintained by inhalation of isoflurane in a face mask (1-1 ,5%-20%). Mice were positioned on a stereotaxic frame (Kopf) equipped with a 10 pL 1701 Hamilton syringe (Dutscher, 074493) and a tailor-made 32-gauge needle (Dutscher, 074753). A mixture of AAV9-Tyrosinase and AAVrh. lO-CYP46Al or AAVrh. lO-null recombinant vectors was injected bilaterally into the mouse SNpc in a final volume of 1 pL at a rate of 0.2 pL/minute.
Viral preparation corresponding to 1.109 vg/SNpc for the AAVrh. lO-CYP46Al or the AAVrh.10-null and 4,5.109 vg/SNpc for the AAV9-Tyrosinase were injected into the right and the left SNpc at the stereotaxic coordinates: 2,9 mm caudal to the bregma, 1,3 mm lateral to midline and 4,2 mm ventral to the skull surface. The pipette was left in place for 5 min after injection to avoid leakage. After surgery, mice were placed in an incubator for optimized recovery from anaesthesia.
AA V plasmid design and vector production
Vector production has been described elsewhere (Hudry et al., 2010). The viral constructs for AAVrh.10- null and AAVrh.10-CYP46A1 -HA contained the expression cassette consisting of the human /NAz/genes, driven by a CMV early enhancer/chicken P-actin (CAG) synthetic promoter (CAG) surrounded by inverted terminal repeats (ITR) sequences of AAV2. These vectors were produced and purified by Atlantic Gene therapies (INSERMU1089, Nantes, France).
AAV9-Tyrosinase contained the expression cassette consisting of the human Tyrosinase gene, driven by the CMV synthetic promoter surrounded by inverted terminal repeats (ITR) sequences of AAV2, or the AAV9-null, were kindly provided by Dr Jose Luis Lanciego and produced by the University of Barcelona (Spain).
Mice behavior assessment
Rotarod: Mice were tested once a month from 1 -month to 6-month post-injection. Each daily session included a 5-minute training trial at 4 rpm on the rotarod apparatus (Bioseb). 30 minutes later, mice were tested for three consecutive accelerating trials with the speed linearly increasing mode (from 4 to 40 rpm overs 300 seconds). The latency to fall from the rod (duration in seconds) was recorded for each trial.
Gait analysis: Mice were acclimated in the testing room for 30 minutes prior to recordings. Mice were placed in the corridor (Runway, CleverSys Inc.). Once the mouse entered in the view of the camera located below the walkway, it recorded for one passage at 2000 frames per second (AVI format). The recordings were then viewed and analysed blind using Fiji (ImageJ) software.
Tissue collection
Mice were anesthetized with pentobarbital (Euthasol 180 mg/kg) solution and perfused transcardially with phosphate buffered saline (PBS). Brains were collected and post-fixed in PFA 4% prior to inclusion for histology analysis.
Histological analysis
Coronal brain sections (20 m for the SNpc, 30 pm for the striatum) were cut on a freezing microtome (Leica), collected serially in a cryoprotective solution, and stored at -20°C until use. Immunostainings were carried out on frozen free-floating sections. Slices were washed in PBS 0,lM and blocked in PBS 0,lM Triton 0,03% containing 5% normal goat serum (NGS, Gibco) for 1 hour. Sections were then incubated with the respective primary antibody (see Antibodies section) in PBS-Triton 0,03% containing 3% NGS over night at 4°C. After three successive washes of 5 minutes in PBS, brain slices wete incubated for 1 hour and 30 minutes with seconday Alexa Fluor-conjugated (Invitrogen) antibodies directed against the species of the primary antibody at room temperature. Slices were stained in a DAPI solution, mounted in Fluoromount-G™(Invitrogen) and conserved at 4°C until microscopy analysis. The immunoassayed slides were then scanned using a slide scanner (Axio Scan Z. l, Zeiss). Unbiased stereological counting in the SNpc was performed on 8 brain sections per mouse (from Cl to C8) to obtain the entire structure, then the number of cells was approximated by integral calculation. Positive cells were counted using artificial intelligence (Aiforia). Optical density of dopaminergic terminals in the striatum was measured using Fiji software (ImageJ).
Antibodies
The following primary antibodies were used: rabbit anti-TH (Novus Biologicals, NB300-109) at 1 :2500; mouse anti-HA (Biolegend, 901516) at 1 : 1000. Secondary antibodies for immunoblotting were the appropriate goat anti-mouse or anti-rabbit Alexa-Fluor 488 or Alexa-Fluor 647 (Invitrogen)
Results:
The inventors investigated in vivo the impact of CYP46A1 in a recent mouse model of Parkinson’s disease, the Neuromelanin mouse model. The principle of this model lies in the fact that the Tyrosinase enzyme, which is responsible for the production of neuromelanin (NM), is expressed in the SNpc of mice using an AAV vector. In humans, dopaminergic neurons expressing NM are particularly susceptible to degeneration. NM is absent from the substantia nigra of rodents, and over-expressing it leads to a PD-like phenotype. Interestingly, it has been shown that p62-positive Lewy body-like inclusions are found in the substantia nigra of rodents in this model (Carballo-Carbajal et al., 2019).
To this end, an AAV vector (AAV9-Tyrosinase) or its control (Sham, AAV9-null) was injected into the SNpc of mice. This vector was co-administered with a vector encoding CYP46Al(AAV.rhlO-CYP46Al) or a control vector not encoding any protein (EV, AAV.rhlO-
null). First, the authors show that CYP46A1 significantly prevents the loss of dopaminergic neurons in the SNpc of Neuromelanin mice (Figure 8A). Tyrosinase mice treated with AAVrh. lO-CYP46Al lost significantly fewer neurons than Tyrosinase mice treated with AAVrh.10 control. This significant reduction in the loss of dopaminergic neurons is correlated with the prevention of the loss of dopamine endings in the striatum (Figure 8B). It should be noted that dopaminergic degeneration is particularly strong in this model, and yet is reduced by AAVrh.lO-CYP46Al.
The loss of around 50% of the dopaminergic neurons in the SNpc and around 50% of the dopaminergic endings in the striatum is necessary for motor symptoms to appear in humans (Kordower et al., 2013). In the Neuromelanin mouse model, the inventors show a reduction in motor function as assessed by Rotarod test (Figure 9A) and in the analysis of spontaneous gait (Figures 9B-9C). Impairment of motor function assessed by rotarod in Tyrosinase mice was significant at 2-, 3- and 5-months post-injection of AAVs. At these time points, CYP46A1- treated Tyrosinase mice showed no significant impairment of rotarod performance, demonstrating that CYP46A1 prevents this impairment (Figure 9A). In addition, the forepaw gait of Tyrosinase mice is significantly impaired, as can be seen through the increase in stride length. This gait impairment, more specific to the pathology, is significantly prevented by CYP46A1 treatment (Figure 9B). The decrease in stride length is only significant for the front (not hind) limbs in Tyrosinase mice, although there is a trend for the hind legs, also prevented by CYP46A1. This is expected when lateral SNpc damage is induced, which is explained by the AAV-Tyrosinase vector injection coordinates used.
This suggests that CYP46A1 could have a beneficial effect on PD mouse models, in particular on models that reproduce cellular mechanisms close to those producing Lewy bodies in humans.
Conclusion:
All these data identify for the first time CYP46A1 as a relevant therapeutic target for alpha-synucleinopathies and more particularly for Parkinson disease and the useful of a vector comprising the full sequence of cholesterol 24-hydroxylase encoding nucleic acid to treat these diseases.
REFERENCES:
Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
Burlot MA. Et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum Mol Genet 2015 Nov l;24(21):5965-76.
Cassia N. Cearley. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and RhlO in the mouse brain. Molecular Therapy 2009. Jackson-Lewis Vernice, Serge Przedborski. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007.
Hudry E. et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther. 2010 Jan;18(l):44-53. doi: 10.1038/mt.2009.175. Epub 2009 Aug 4.
Wurtz G. et al. CYP46A1 as a Relavant Target to Treat ALS Pathology Independent from its Origin. Molecular Therapy 30 (4), 569-569, 2022.
Carballo-Carbajal, I. et al. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis (2019). Nat Commun 10, 973.
Claims
1. A vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
2. The vector for use according to the claim 1, comprising a nucleic acid sequence that encodes the amino acid sequence SEQ ID N°2.
3. The vector for use according to any claims 1 to 2, comprising the nucleic acid sequence SEQ ID N°1 or a variant thereof.
4. The vector for use according to any claims 1 to 3, which is selected from the group of adenovirus, lentivirus, retrovirus, herpesvirus and Adeno-Associated Virus (AAV) vectors.
5. The vector for use according to any claims 1 to 4 which is an AAV vector.
6. The vector for use according to the claim 5, which is an AAV 10 vector or an AAVrh.10 vector.
7. The vector for use according to any claims 1 to 6, which is to be administered intravenously.
8. The vector for use according to claims 1 to 7 wherein the alpha-synucleinopathie is the Parkinson disease (PD), the Parkinson disease with dementia, dementia with Lewy bodies or multiple-system atrophy (MSA).
9. A pharmaceutical composition for use in the treatment of alpha-synucleinopathies in a subject in need thereof which comprises a therapeutically effective amount of a vector as defined in any one of claims 1 to 8.
10. A method of treating alpha-synucleinopathies in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a vector which comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22306556.6 | 2022-10-14 | ||
EP22306556 | 2022-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024079317A1 true WO2024079317A1 (en) | 2024-04-18 |
Family
ID=84331193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/078486 WO2024079317A1 (en) | 2022-10-14 | 2023-10-13 | Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024079317A1 (en) |
-
2023
- 2023-10-13 WO PCT/EP2023/078486 patent/WO2024079317A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6887008B2 (en) | Gene therapy for spinal cord disease | |
EP3364970B1 (en) | Gene therapy for use in treating lysosomal storage disease | |
JP6397391B2 (en) | Gene therapy for neurodegenerative disorders | |
US11040113B2 (en) | Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia | |
US10087224B2 (en) | Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions | |
EP3254702B1 (en) | Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities | |
EP2187898B1 (en) | Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease | |
AU2017362491B2 (en) | Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2 | |
US20130209410A1 (en) | Expression vector for cholesterol 24 -hydrolase in therapy of huntington's disease | |
CN114555813A (en) | Expression vector of cholesterol 24-hydrolase for treating Rett syndrome | |
WO2024079317A1 (en) | Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies | |
US20230174994A1 (en) | Engineered parkin and uses thereof | |
US20230151390A1 (en) | Vectors for the treatment of acid ceramidase deficiency | |
US20220211737A1 (en) | Compositions and methods for treatment of friedreichs ataxia | |
JP2023534293A (en) | Methods and compositions for the treatment of fragile X syndrome | |
EP3873511B1 (en) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis | |
US20230183741A1 (en) | Disease correction by delivery of aav8 vectors expressing codon optimized naglu | |
US20240025953A1 (en) | Compositions and methods for inhibiting alpha-synuclein aggregation | |
JP2022531177A (en) | Methods for treating neurodegenerative disorders |